CHRISTY MANSPILE: Open Payments
NPI 1366801136 · LYNCHBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$927 in 47 payments from 14 companies in 2025. Trend: 2023 $1,159 · 2024 $1,284 · 2025 $927
Food & beverage: $927
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $163 |
| Janssen Biotech, Inc. | 6 | $126 |
| Celltrion USA Inc. | 2 | $53 |
| GENZYME CORPORATION | 2 | $52 |
| Ardelyx, Inc. | 3 | $51 |
| Ipsen Biopharmaceuticals, Inc | 2 | $47 |
| Novo Nordisk Inc | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
Products named: TREMFYA, SKYRIZI, ENTYVIO, RINVOQ, EOHILIA, VEGZELMA, IBSRELA, IQIRVO.
Industry payments across VA — which companies pay providers there.
